Please assess the completion status of the following clinical trial:

Trial Title: Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Drug naive~* Hemoglobin (Hb) A1c \>= 7.0% and \<= 10.0% (\>10% and \<= 12% for open label arm)~* Fasting C-peptide \>= 1 ng/mL~* Body mass index \<= 40 kg/m2~Exclusion Criteria:~* Symptomatic poorly controlled diabetes~* Recent cardiac or cerebrovascular event~* Serum creatinine \>= 1.5 mg/dL for males and \>= 1.4 mg/dL for Women of Child Bearing Potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 2.5 mg (A) (Type: EXPERIMENTAL): Metformin 500-2000 mg (as needed for rescue)
- Saxagliptin 5 mg (B) (Type: EXPERIMENTAL): Metformin 500-2000 mg (as needed for rescue)
- Saxagliptin 10 mg (C) (Type: EXPERIMENTAL): Metformin 500-2000 mg (as needed for rescue)
- Placebo (D) (Type: PLACEBO_COMPARATOR): Metformin 500-2000 mg (as needed for rescue)
- Open-Label Treatment Cohort (Direct Enrollees) (E) (Type: EXPERIMENTAL): Saxagliptin 10 mg~Metformin 500-2000 mg (as needed for rescue)

Based on this trial design, predict the completion outcome and termination type (if applicable).